WASHINGTON — Purdue Pharma L.P. has become a member of health policy research group The National Pharmaceutical Council (NPC).

Tracy Mayne

NPC said Dr. Tracy Mayne, head of medical affairs strategic research at Purdue Pharma, will serve as the pharmaceutical company’s representative on the NPC board of directors.

“NPC’s research and activities are helping to drive the discussion around the importance of defining value as patients seek care centered on their needs,” Mayne stated. “Purdue Pharma welcomes the opportunity to work with NPC and other member companies to advance the conversation on ensuring patient access to high-value care and improving the efficiency and effectiveness of our health care delivery systems.”

Stamford, Conn.-based Purdue Pharma is engaged in the research, development, production and distribution of prescription and over-the-counter medications, as well as hospital products. Purdue Pharma and associated U.S. companies are known for pioneering research in chronic pain and opioids with abuse-deterrent properties.

“I am pleased to welcome Purdue Pharma and Dr. Mayne to NPC,” commented NPC president Dan Leonard. “Dr. Mayne brings a wealth of expertise in medical affairs and health policy development that will be an invaluable resource in our efforts to further address issues such as the conduct and application of real-world evidence and the shift toward high-value, patient-centered care. We look forward to Dr. Mayne’s participation on our board.”

The NPC board consists of a representative from each member company. Other NPC members include AbbVie, Allergan, Amgen, Astellas Pharma US, AstraZeneca, Bayer HealthCare Pharmaceuticals, Biogen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Pfizer, Sanofi, Takeda Pharmaceuticals USA and Teva Pharmaceuticals.